Immunization against Lung Cancer? Biontech tests new Vakzin

2020 goes through the main pharmaceutical industry Biontech by the development of mRNA-based Corona-impfstoffs international Bekanntheit. This specialty is the Firm on the largest Detwicklung of Krebsmedikamenten. There are other pharmaceutical companies that have carried out an impfung to Krebsarten vervarieden.

In the treatment of lung cancer, biotechnology is now entering the next phase of a clinical trial at a British hospital and first provide patients with a new and effective lung cancer.

Erster Mensch against Lungenkrebs impftt

67-year-old Janusz Racz from London is the first test subject of the study, the new Krebsimpfstoff “BNT116” on August 23. The study at the University of the University College London Hospital (UCLH) continued, where Racz held the first dose. Six injections were made in five minutes. Each dose has discovered an uninteresting RNA alien. So the treatment becomes bigger and faster than 60 weeks in the unused dosage of the new biotech impact substances.

The Brit is one of 130 Test subjects, die an der international Studie teilnehmen. Unter ihnen sind Teilnehmer:innen im Spring Stadium for employees of Eingriffen or Strahlentherapieën, Probanden in the stadium or with reclaimed Krebsleiden.

For racing is one of the last possibilities in the fight against disease. On May 1, 2024, a tumor has arisen in the rights. It is said that the “Guardian” is a courtesy, after the completion of the treatment, which can lead to a trauma and a trauma – the race during the London Marathon – that is inherited.

Resistance against lung loans: Who is working on the new drug?

This new art of treatment will be different from chemotherapies, while Krebszellen will no longer be treated in the future.

Make sure the new upholstery is on the outside Krebs Immunotherapy for Non-Small Lungenkrebs (NSCLC). The new mRNA substance that attacks the immune system causes the Krebs cells to be identified and entombed.

“The patients’ immune system (becomes) a Bone RNA (mRNA) is characterized by a high tumor marker that can be identified. While the immune system, Krebscelllen, express, recognize and combat these markers,” which is in the press conference of the British Clinic on August 23.

So if the ideal situation now is to overcome the credit risks, the care for patients will compensate for the immunity that the credit provision is secured.

“The amplification is a fact, and man can remove the antigen in the Krebszelle and then inject it. This technology is the greatest stage of Krebsbehandlung,” as Siow Ming Lee, a physician of medicine at UCLH, said of the national study guide.